Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01077024 · ClinicalTrials.gov registry record · Phase 3
Smoking-Cessation and Stimulant Treatment (S-CAST)
A Phase 3 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 3
- Development phase
- 538
- Enrollment target
NCT01077024: Completed Phase 3 study, sponsored by University of Cincinnati.
NCT01077024 is a Phase 3 study that has completed, run by University of Cincinnati. The registered enrollment target is 538 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01077024, a Phase 3 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 538 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the impact of substance-abuse treatment as usual plus smoking-cessation treatment (TAU+SCT), relative to substance-abuse treatment as usual (TAU), on drug-abuse outcomes. Specifically, this study will evaluate whether concurrent smoking-cessation treatment improves, worsens, or has no effect on stimulant-use outcomes in smokers who are in outpatient substance-abuse treatment for cocaine or methamphetamine dependence.
Primary Outcome
Stimulant-free week results (no cocaine, methamphetamine and amphetamine use) were obtained by combining the urine drug screens (UDS) and the self-reported Timeline Follow-Back (TLFB). At the group level, this outcome translates into the percentage of weeks in each study arm that are stimulant-free.
Interventions
- OTHER Smoking-cessation treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 538 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
What the finished NCT01077024 record still lists
NCT01077024 is an interventional study that assigns participants to a tested intervention. The registered 538 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 1 intervention - of which Smoking-cessation treatment is the first listed.
NCT01077024 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01077024 about?
NCT01077024 is a clinical study titled "Smoking-Cessation and Stimulant Treatment (S-CAST)". The primary objective of this study is to evaluate the impact of substance-abuse treatment as usual plus smoking-cessation treatment (TAU+SCT), relative to substance-abuse treatment as usual (TAU), on drug-abuse outcomes. Specifically, this study will evaluate whether concurrent smoking-cessation tr...
What is the current status of trial NCT01077024?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 538 participants. The study started on 2010-02. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01077024?
The interventions under investigation include: Smoking-cessation treatment (OTHER).
Who is sponsoring clinical trial NCT01077024?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01077024's enrollment target sits among peer trials
538 700th of 2000 higher than 1,300 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03772028 · 538 participants · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- NCT06538038 · 538 participants
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia